Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Tuesday, September 19, 2017
 
Recommended for you
State AGs gang up on opioid makers, 41 now in coalition
Seeking Alpha • Douglas W. House
Surgeons lacked caution in use of vaginal mesh implants, doctor admits
The Guardian • Christopher Knaus
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Fool.com: The Motley Fool • Keith Speights
3 Things In Biotech You Should Learn Today: September 16, 2017
Seeking Alpha • Zach Hartman
Tremfya shows durable efficacy in plaque psoriasis
Week in Review • Jaime De Leon
Lackawanna County to lead path in suing pharmaceutical companies over opioid crisis
Pocono Record • Jeff Horvath, Pa., Scranton, The Times-Tribune
Johnson & Johnson - This Is A Dividend Machine
Seeking Alpha • Charles Fournier
The Smartest Move Johnson & Johnson Has Made All Year
Fool.com: The Motley Fool • Sean Williams
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
Fool.com: The Motley Fool • Todd Campbell
Why Pfizer Is Pushing the Dow to All-Time Highs
24/7 Wall St. • 247chrislange
 
Recommended for You
Johnson & Johnson, McKesson Corp
State AGs gang up on opioid makers, 41 now in coalition
Seeking AlphaDouglas W. House
Realizing a golden opportunity to extract money from corporations, 41 state attorneys general have expanded their investigations into alleged misleading marketing by drug firms aimed at boosting sales of prescription opioid medications and contributing greatly to the opioid addiction crisis. Endo International...
Share
Health Care Industry, Johnson & Johnson
Surgeons lacked caution in use of vaginal mesh implants, doctor admits
The GuardianChristopher Knaus
The corporate giant Johnson & Johnson says it acted “ethically and responsibly” in developing and selling its controversial transvaginal mesh implants, which have left hundreds of Australian women with chronic and debilitating pain. A Senate inquiry is currently examining the impact of...
Share
Johnson & Johnson, Merck & Co., Inc.
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Fool.com: The Motley FoolKeith Speights
Johnson & Johnson (NYSE:JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period. Perhaps the most surprising disappointment of all was that pharmaceutical segment revenue was...
Share
Cancer, Epidemiology
3 Things In Biotech You Should Learn Today: September 16, 2017
Seeking AlphaZach Hartman
Summary Roche is the next in line to feel the FDA hammer. Johnson & Johnson tries to move toward the front of the line in advanced prostate cancer. Mirati Therapeutics blasts off on positive lung cancer data. Welcome to another edition of...
Share
Abbott Laboratories, Health Care Industry
Tremfya shows durable efficacy in plaque psoriasis
Week in ReviewJaime De Leon
The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported two-year data from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya guselkumab on Saturday showing that the drug maintained long-term efficacy in patients with moderate-to-severe...
Share
Biotechnology, Health Care Industry
Lackawanna County to lead path in suing pharmaceutical companies over opioid crisis
Pocono RecordJeff Horvath, Pa., Scranton, The Times-Tribune
Flanked by law enforcement, county officials and victims of the opioid crisis plaguing the region, Commissioner Patrick O’Malley made a bold statement today: “It’s Lackawanna County versus the pharmaceutical companies.” O’Malley made the remarks at a press conference announcing the county’s intent...
Share
Actelion Pharmaceuticals, Finance
Johnson & Johnson - This Is A Dividend Machine
Seeking AlphaCharles Fournier
Summary JNJ has been and will remain a long-term hold in our retirement accounts and in the FFJ Portfolio. JNJ is 1 of only 2 companies rated AAA by Moody’s, which provides peace of mind that my investment is not at risk....
Share
Actelion Pharmaceuticals, Health Care Industry
The Smartest Move Johnson & Johnson Has Made All Year
Fool.com: The Motley FoolSean Williams
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is what you might call a stalwart in the portfolios of risk-averse, income-seeking long-term investors. It's about as rock-solid as they come in the healthcare sector, with geographic and operational diversity, a AAA credit rating from...
Share
Cancer, Johnson & Johnson
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
Fool.com: The Motley FoolTodd Campbell
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE:PFE) Xtandi quickly gained ground on Johnson & Johnson's (NYSE:JNJ) multibillion-dollar Zytiga. However, Xtandi's momentum has slowed, leaving some to question if Pfizer's $14...
Share
Cancer, Johnson & Johnson
Why Pfizer Is Pushing the Dow to All-Time Highs
24/7 Wall St.247chrislange
Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day. … Continue reading →
Share